Table 2.

Peripheral blood and bone marrow mononuclear cell values

	NC		HC		Tx		Post-Tx

	Vehicle	Losartan	Vehicle	Losartan	Vehicle	Losartan	Vehicle	Losartan
PB WBC × 10⁶ mm^-3	9.1 ± 1.0	10.3 ± 1.3	10.1 ± 0.9	10.9 ± 1.5	10.6 ± 1.5	10.6 ± 2.1	10.1 ± 2.9	10.4 ± 1.7
PB Monocytes × 10⁶ mm^-3	2.6 ± 0.2	2.6 ± 0.2	2.5 ± 0.2	2.3 ± 0.3	2.9 ± 0.3	2.5 ± 0.3	2.4 ± 0.2	2.6 ± 0.4
BMMNC × 10⁶ mm^-3	55 ± 6	50 ± 6	72 ± 6^*	72 ± 5^*	78 ± 6^*	62 ± 5^*^†	81 ± 5^*	73 ± 6^*
PB CD14⁺/CD45⁺ Gate,%	76 ± 6	71 ± 7	81 ± 8	75 ± 4	72 ± 8	80 ± 8	76 ± 9	80 ± 9
PB Monocyte CD11b⁺,%	2.2 ± 0.1	2.3 ± 0.6	11.6 ± 2.3^*	12.4 ± 4.2^*	9.4 ± 2.2^*	3.6 ± 1.1^†	9.8 ± 2.8^*	12.0 ± 2.8^*
BMMNC Monocyte CD11b⁺,%	6.3 ± 0.6	8.3 ± 0.4	36.6 ± 6.3^*	42.4 ± 7.2^*	39.7 ± 8.2^*	13.6 ± 4.4^†	39.2 ± 7.8^*	32.0 ± 6.9^*

P < 0.05, differences from NC baseline.

^†

P < 0.05, difference from vehicle-treated group.

Tx, 15 weeks of treatment; Post-Tx, 6 weeks post-treatment. PB WBC, peripheral blood white blood cell counts; BMMNC, bone marrow mononuclear cell counts.